


## 5-HT<sub>3</sub> antagonist 5

<b>Cat. No.:</b>	HY-148038		
<b>CAS No.:</b>	901599-43-7		
<b>Molecular Formula:</b>	C <sub>16</sub> H <sub>13</sub> N <sub>3</sub> O <sub>2</sub>		
<b>Molecular Weight:</b>	279.29		
<b>Target:</b>	5-HT Receptor		
<b>Pathway:</b>	GPCR/G Protein; Neuronal Signaling		
<b>Storage:</b>	Powder	-20°C	3 years
		4°C	2 years
	In solvent	-80°C	6 months
		-20°C	1 month



### SOLVENT & SOLUBILITY

#### In Vitro

DMSO : 20.83 mg/mL (74.58 mM; ultrasonic and warming and heat to 60°C)

Concentration	Mass		
	1 mg	5 mg	10 mg
1 mM	3.5805 mL	17.9025 mL	35.8051 mL
5 mM	0.7161 mL	3.5805 mL	7.1610 mL
10 mM	0.3581 mL	1.7903 mL	3.5805 mL

Please refer to the solubility information to select the appropriate solvent.

### BIOLOGICAL ACTIVITY

#### Description

5-HT<sub>3</sub> antagonist 5 is a quinoxalin-2-carboxamide compound, a 5-HT<sub>3</sub> receptor antagonist. 5-HT<sub>3</sub> antagonist 5 exerts antagonism on 5-HT<sub>3</sub> agonist and 2-methyl-5-HT, and shows anti-depressant effect in mice<sup>[1]</sup>.

#### IC<sub>50</sub> & Target

5-HT<sub>3</sub> Receptor

#### In Vitro

5-HT<sub>3</sub> antagonist 5 (compound 4c) exhibits 5-HT<sub>3</sub> receptor antagonisms in longitudinal muscle myenteric plexus preparation from guinea pig ileum against 5-HT<sub>3</sub> agonist, 2-methyl-5-HT, with pA<sub>2</sub> value of 5<sup>[1]</sup>.  
MCE has not independently confirmed the accuracy of these methods. They are for reference only.

#### In Vivo

5-HT<sub>3</sub> antagonist 5 (compound 4c) (1 mg/kg; i.p.; single dose) decreases the duration of immobility and shows anti-depressant effect in FST mice<sup>[1]</sup>.  
MCE has not independently confirmed the accuracy of these methods. They are for reference only.

Animal Model:	Swiss albino mice (23 ± 2 g) <sup>[1]</sup>
---------------	---

Dosage:	1 mg/kg
Administration:	Intraperitoneal injection; single dose; locomotor scores tested 10 min after administration
Result:	Reduced the duration of immobility as compared to the vehicle-treated (control) group. Showed no effect on the locomotion of mice as observed in spontaneous locomotor activity.

## REFERENCES

[1]. Mahesh R, et al. Design, synthesis and structure-activity relationship of novel quinoxalin-2-carboxamides as 5-HT<sub>3</sub> receptor antagonists for the management of depression. *Bioorg Med Chem Lett*. 2010 Nov 15;20(22):6773-6.

**Caution: Product has not been fully validated for medical applications. For research use only.**

Tel: 609-228-6898

Fax: 609-228-5909

E-mail: [tech@MedChemExpress.com](mailto:tech@MedChemExpress.com)

Address: 1 Deer Park Dr, Suite Q, Monmouth Junction, NJ 08852, USA